TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8989016
Drug: Glycopyrrolate 8
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 8 micrograms/kg and neostigmine 50 micrograms/kg (Group G)
Study: 8484510
Drug: Propofol (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (approximately 3 micrograms/mL) with 60% nitrous oxide
Study: 8484510
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion (100 micrograms.kg-1 x min-1) during propofol anesthesia
Study: 3117150
Drug: Nebulizer administration
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer administration of 4 mg terbutaline
Study: 3117150
Drug: Nebuhaler administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebuhaler administration of 4 mg terbutaline
Study: 28449618
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual face‐to‐face physical therapy)
Study: 20502134
Drug: Sublingual tizanidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tizanidine HCl (8 mg)
Study: 20502134
Drug: Oral tizanidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tizanidine HCl (8 mg)
Study: 11754710
Drug: Rofecoxib, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib, 25 mg/d
Study: 7614523
Drug: Naproxen, 500
Normalized name: Naproxen, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen, 500 mg twice daily
Study: 2000833
Drug: High-sodium polymeric-glucose
Normalized name: glucose / sodium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium polymeric-glucose solution (maltodextrins 18 g Glucidex 12/L + 2.5 g NaCl/L)
Study: 2000833
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral rehydration solution
Study: 6510015
Drug: 0.05% diflorasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% diflorasone diacetate ointment, once a day
Study: 6510015
Drug: 0.1% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% betamethasone valerate ointment, twice a day
Study: 30481110
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of MMRV vaccine
Study: 30481110
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of MMRV vaccine
Study: 1139387
Drug: Glycopyrrolate 0.2
Normalized name: glycopyrrolate 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 0.2 mg
Study: 22972032
Drug: Prednisone 15
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 15 mg daily
Study: 22972032
Drug: Prednisone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 7.5 mg daily
Study: 18046293
Drug: Propofol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (20 mg bolus and 1.0 mg x kg(‐1) x h(‐1) infusion)
Study: 18046293
Drug: Midazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1 mg bolus and 1.0 mg x h(‐1) infusion)
Study: 7825408
Drug: Topical cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporin 2% in olive oil
Study: 2449651
Drug: Gamma-globulin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-globulin infusion (GG)
Study: 2449651
Drug: Aspirin only
Normalized name: Aspirin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin only (Control)
Study: 31236580
Drug: Objective measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Objective measures for ocular and oral dryness
Study: 17255296
Drug: New targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: New targeted therapies
Study: 26475054
Drug: Albuterol MDPI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDPI (180 μg, 2 inhalations of 90 μg each)
Study: 26831652
Drug: Albuterol MDPI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDPI
Study: 7898828
Drug: Esterified estrogens
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogens (1.25 mg) and methyltestosterone (2.5 mg) daily for 2 years
Study: 7898828
Drug: Esterified estrogens
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogens (1.25 mg) daily for 2 years
Study: 31017822
Drug: ACT017 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT017 (doses ranging from 62.5 to 2000 mg)
Study: 27557937
Drug: Ferric pyrophosphate
Normalized name: Ferric Pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric pyrophosphate citrate (2.5, 5.0, 7.5, or 10 mg administered over 4 hours; 15 or 20 mg administered over 12 hours)
Study: 29103664
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg and 300 mg
Study: 19791825
Drug: All new
Approvals — FDA: no, EMA: no, PMDA: no
Description: All new biological agents
Study: 11316024
Drug: LASIK custom
Approvals — FDA: no, EMA: no, PMDA: no
Description: LASIK custom treatment
Study: 11316024
Drug: LASIK conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: LASIK conventional treatment
Study: 9397101
Drug: Misoprostol tablets
Normalized name: Misoprostol Tablets
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol tablets (n = 234)
Study: 9397101
Drug: Misoprostol gel
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol gel (n = 233)
Study: 8248841
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with wedge filter (group B)
Study: 8248841
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy without wedge filter (group A)
Study: 8248841
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with wedge filter for large T1a lesions (group B)
Study: 8248841
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy without wedge filter for large T1a lesions (group A)
Study: 2884191
Drug: Penbutolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 40 mg
Study: 27576775
Drug: More intensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intensive antiplatelet therapy (meta-analysis across 4 trials)
Study: 22484638
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg daily for 7 days)
Study: 20845811
Drug: Panitumumab (single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (single-agent treatment)
Study: 20845811
Drug: Cetuximab (single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (single-agent treatment)
Study: 15892486
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment (5 globules in a potency of 200c given at 12h interval during ICU stay)
Study: 9915448
Drug: L-arginine (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (1,500 mg daily)
Study: 7776995
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy with INR between 2.0 and 3.9
Study: 7776995
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy with INR below 2.0
Study: 7776995
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy with INR of 5.0 or above
Study: 2333695
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose penicillin
Study: 31496678
Drug: Tiotropium/olodaterol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium/olodaterol combination therapy
Study: 31496678
Drug: Tiotropium monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium monotherapy
Study: 26363637
Drug: Azithromycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (30 mg/kg weekly for up to 24 months)
Study: 19846149
Drug: Doxazosin (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (0.03 mg/kg daily)
Study: 31520576
Drug: Ibuprofen (control)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (control)
Study: 17110825
Drug: Methylphenidate (OROS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (OROS MPH, Concerta) 18‐54 mg/d
Study: 1451052
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 5‐fluorouracil
Study: 14740125
Drug: Additional administration
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional administration of leucovorin or levamisole
Study: 14740125
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with new drugs (capecitabine, UFT, irinotecan, oxaliplatin)
Study: 8674405
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg daily of tauroursodeoxycholic acid
Study: 8674405
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg daily of tauroursodeoxycholic acid
Study: 8674405
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg daily of tauroursodeoxycholic acid
Study: 1455418
Drug: Induced hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced hypertension chemotherapy (IHC) with 5‐fluorouracil, adriamycin, and mitomycin C
Study: 1455418
Drug: Non-induced hypertension
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-induced hypertension chemotherapy (same regimen without hypertension)
Study: 1455418
Drug: Induced hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced hypertension chemotherapy (IHC)
Study: 6732937
Drug: Hydralazine (apressine)
Normalized name: hydralazine Oral Tablet [Apresoline]
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydralazine (apressine) 50-100 mg
Study: 6732937
Drug: Endralazine (mirethilan)
Normalized name: endralazine
DrugBank: Endralazine (DB13435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endralazine (mirethilan) 5-15 mg
Study: 6732937
Drug: Prazosine (pratsiol)
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prazosine (pratsiol) 2-5 mg
Study: 6732937
Drug: Propranolol (obsidan)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (obsidan) 80-120 mg
Study: 27112842
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone (GnRH; 100 μg IV)
Study: 25041868
Drug: Intensive intonation‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive intonation‐based speech therapy for 15 weeks
Study: 25041868
Drug: Intensive intonation‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive intonation‐based speech therapy
Study: 22460943
Drug: rizatriptan 10
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rizatriptan 10 mg wafer
Study: 14576536
Drug: 0.56 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.56 mg/kg succinylcholine
Study: 10588598
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg plus continuing inhaled beclomethasone
Study: 10588598
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet plus continuing inhaled beclomethasone
Study: 10588598
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg and inhaled placebo
Study: 10588598
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet and inhaled placebo
Study: 15167592
Drug: Ketoconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (100 mg/day)
Study: 2401123
Drug: Oral propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propafenone (300 to 450 mg)
Study: 2401123
Drug: Intravenous propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone (35 to 50 mg)
Study: 30121808
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with paclitaxel plus bevacizumab (2×4 cycles)
Study: 30121808
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with paclitaxel plus bevacizumab (8 cycles)
Study: 30121808
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with paclitaxel plus bevacizumab
Study: 30121808
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with paclitaxel plus bevacizumab
Study: 26761213
Drug: Cisplatin with
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin with pemetrexed and concurrent late course accelerated hyperfractionated radiotherapy (LCAHRT)
Study: 26761213
Drug: Cisplatin with
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin with vinorelbine and concurrent late course accelerated hyperfractionated radiotherapy (LCAHRT)
Study: 25261187
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality training as an adjunct to conventional therapy
Study: 25261187
Drug: Dose-matched conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched conventional training
Study: 21054824
Drug: Proton radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton radiation therapy (72 Gy E ± 5%)
Study: 21054824
Drug: Carbon ion
Normalized name: CARBON ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon ion radiation therapy (63 Gy E ± 5%)
Study: 16272621
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium supplementation
Study: 8913468
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin 1 g
Study: 8913468
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin 2 g
Study: 8913468
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin 4 g
Study: 8913468
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin (all doses)
Study: 1905451
Drug: 6.25 mg
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.25 mg irtemazole
Study: 1905451
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg irtemazole
Study: 1905451
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg irtemazole
Study: 1905451
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg irtemazole
Study: 6132891
Drug: pindolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol (15 mg daily)
Study: 6132891
Drug: acebutolol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol (500 mg daily)
Study: 6132891
Drug: acebutolol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol (500 mg daily) after 16 months
Study: 27510655
Drug: Colonic administration
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonic administration of 13C-labelled acetate
Study: 27510655
Drug: Colonic administration
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonic administration of 13C-labelled propionate
Study: 27510655
Drug: Colonic administration
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonic administration of 13C-labelled butyrate
Study: 26717861
Drug: Carvedilol 6.25mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 6.25mg, twice daily during the run-in period
Study: 24980672
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg once daily (n=9)
Study: 24980672
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg once daily (n=7)
Study: 24980672
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Aliskiren and Ramipril)
Study: 18987057
Drug: High-dose bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bupivacaine (Control)
Study: 14871429
Drug: CsA trough
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA trough levels lower than 300 ng/mL
Study: 12238832
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg tranexamic acid (TA) followed by infusion of 1 mg/kg per hour during the operation
Study: 7977174
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg p.o. 1 hour prior to chemotherapy, repeated after 6 and 12 hours plus dexamethasone 20 mg i.v. 40 minutes prior to chemotherapy
Study: 7977174
Drug: High-dose metoclopramide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide, dexamethasone, and orphenadrine (Control)
Study: 7977174
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg PO t.i.d. days 2 and 3
Study: 7977174
Drug: Metoclopramide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.5 mg/kg p.o. q.i.d. and dexamethasone 8 mg i.m. b.i.d. days 2 and 3 (Control)
Study: 27316489
Drug: 50mg/kg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg/kg of magnesium sulfate (MS) in 100ml 0.9% NaCl solution over 20min before anesthesia induction (Group A)
Study: 27316489
Drug: 100ml 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ml 0.9% NaCl solution (Group B)
Study: 26353411
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg day(-1))
Study: 22625877
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg every 12 h for 4 days with a single 15 mg dose of pioglitazone on day 3
Study: 22625877
Drug: Pioglitazone alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone alone (15 mg)
Study: 15905227
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein preload plus ID saline perfusion
Study: 15905227
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein preload plus ID fat perfusion
Study: 10399449
Drug: ICU group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICU group (preoperative treatment aiming at a CI >= 4.0 l/min/m2)
Study: 12536625
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no special treatment)
Study: 2076441
Drug: Vancomycin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (4 drops of a 5% solution every 8 hours)
Study: 2076441
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no local treatment)
Study: 7033789
Drug: D-penicillamine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (250 mg four times a day)
Study: 28682725
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution gauze (NSS group)
Study: 18083374
Drug: Chemotherapeutic drugs,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutic drugs, immunostimulants, and various vaccines
Study: 16702472
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE; 0.625 mg)
Study: 9832936
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg nicotine
Study: 9832936
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg nicotine
Study: 9832936
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg nicotine
Study: 9832936
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg nicotine
Study: 9832936
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nicotine
Study: 2838426
Drug: Potassium iodide
Normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium iodide (0.5 g, 1.0 g, and 2.0 g)
Study: 31055677
Drug: Visual attention
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Visual attention training (twice a week for 45 min sessions over 3 weeks)
Study: 26493038
Drug: 5‐monthly fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐monthly fixed dosing of Ozurdex
Study: 16491463
Drug: Oral polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polyethylene glycol (PEG) solution (3 litres)